Organization
PD-L1 Cutoff for TNBC Keytruda Benefit Confirmed in KEYNOTE Analyses, But Questions Linger
Findings confirmed advanced TNBC patients with PD-L1 10 or above benefit from Keytruda, but other data show PD-L1 doesn't predict benefit in earlier-stage TNBC.Â
Foundation Medicine Test Nabs FDA Approval as CDx for BRAF Inhibitor Therapeutics for Melanoma
FoundationOneCDx will also automatically be a companion diagnostic for future BRAF inhibitors approved by the FDA that target specific BRAF mutations.
Pan-Cancer Analysis Reveals Unique Features in Tumors From Younger People
Tumors in younger individuals exhibited a dysregulated molecular aging phenotype and were associated with hallmarks of premature senescence.
SABCS Study Highlights Importance of Ranking Biomarker Evidence in Genomic Test Reports
The study showed that metastatic breast cancer patients are more likely to benefit from precision cancer drugs matched based on biomarkers with strong actionability evidence.
Breast Cancer Therapy Response Predicted by Multiomic Machine Learning Model
A team led by researchers at the University of Cambridge analyzed more than 160 pre-treatment tumor biopsies to identify features linked to treatment response.